AHK-Cu is a synthetic copper-binding tripeptide of alanine, histidine and lysine bound to copper(II). Cosmetic labels call it Copper Tripeptide-3. One published study has tested it directly, using human hair follicles and cultured scalp cells. No human clinical trial of AHK-Cu has been published. Nothing shows whether the peptide, the copper, or the complex drives the effects.
A note on research use only
Everything below covers research context and nothing more. This article gives no dosing, no administration routes, no reconstitution steps and no handling protocols. Those instructions sit outside what a research-use-only page can responsibly publish. Readers who need handling or documentation guidance should work from laboratory documentation and qualified regulatory sources.
Quick facts and what AHK-Cu is at the molecular level
Most of the confusion around this peptide starts with its numbers. Writers routinely quote one molecular mass without saying whether they mean the bare peptide or the copper complex. Those are two different things, and the table below keeps them apart.
- Property: Peptide sequence — AHK-Cu: Ala-His-Lys, bound to Cu(II)
- Property: INCI name — AHK-Cu: Copper Tripeptide-3
- Property: Free peptide formula — AHK-Cu: C15H26N6O4
- Property: Free peptide molecular mass — AHK-Cu: Approximately 354.4 Da
- Property: Copper complex molecular mass — AHK-Cu: Approximately 417.96 Da
- Property: CAS registry number — AHK-Cu: Two in circulation, 126828-32-8 and 682809-81-0, with sources disagreeing on which belongs to which form
- Property: Occurs naturally in humans — AHK-Cu: Not established
- Property: Origin — AHK-Cu: Synthetic
- Property: Direct evidence base — AHK-Cu: One published study
- Property: Human clinical trials — AHK-Cu: None published
Several masses float around supplier pages and blogs, including 403, 416.9, 340.85 and 354.4 Da. That spread does not reflect genuine scientific disagreement. It happens when a writer reports the free peptide mass and the complex mass as though they described a single substance. Checking which form a figure refers to resolves nearly every version of the contradiction.
The CAS situation is less tidy. Both 126828-32-8 and 682809-81-0 appear on commercial and technical sources. Neither is usually paired with a statement of which form it identifies. Sources disagree, so this page does not pick one. Treating that mapping as settled would mean inventing certainty nobody has published.
One naming point prevents a common mix-up. Copper Tripeptide-3 is AHK-Cu, while Copper Tripeptide-1 is GHK-Cu. At least one cosmetic publisher has these reversed, which turns a label check into a false confirmation.
Why AHK-Cu keeps showing up next to GHK-Cu
GHK-Cu arrived first and arrived with better paperwork. Researchers isolated it from human plasma in 1973, meaning the body makes it. Its concentration falls with age, which gave decades of research an obvious question to chase. Hundreds of published papers followed that discovery.
Compare that history with AHK-Cu, a synthetic molecule with one direct study behind it. Both are tripeptides, both bind copper, and both appear in the same product categories. Shared structure explains why they get discussed together. It does not transfer evidence from one to the other.
That distinction does real work through the rest of this article. Claims about skin, collagen, wound repair and blood vessel formation come overwhelmingly from GHK-Cu research or from general copper biology. Each one gets labelled where it appears, because borrowed evidence is not the same thing as evidence. Readers wanting the fuller picture on the better-studied molecule can read our explainer on the GHK-Cu peptide alongside this page.
What the copper is doing in the molecule
Copper does not simply sit beside the peptide. Histidine, the middle residue, carries a ring structure that coordinates copper(II) ions, and the resulting complex behaves differently from a copper salt dissolved in water. Binding changes how the metal moves, how stable it stays, and what it can interact with.
Why copper matters biologically is a separate question with a general answer. Copper acts as a cofactor for enzymes involved in connective tissue formation and antioxidant defence. All of that belongs to copper biology at large. None of it was measured for AHK-Cu, and none of it should be read as an AHK-Cu finding.
Which mechanisms have actually been tested and which are assumed
Mechanism talk is where this topic goes wrong fastest. A plausible pathway gets described in confident language, and a reader comes away thinking something was demonstrated. Four labels keep that from happening here.
Tested directly in AHK-Cu research. The 2007 study measured elongation of human hair follicles cultured outside the body and proliferation of cultured human dermal papilla cells. It also measured the ratio of Bcl-2 to Bax, two proteins that influence whether a cell survives. Levels of cleaved caspase-3 and PARP were recorded too, and both are markers associated with cell death. Those are the direct observations, and the next section covers what they do and do not establish.
General copper biology. Copper's role as an enzyme cofactor sits in this category. So does its involvement in connective tissue chemistry. These facts describe the element, not the peptide complex.
GHK-Cu analogy. Collagen stimulation, fibroblast activity, wound repair and angiogenesis claims nearly always trace back to GHK-Cu work. Carrying them across to AHK-Cu is an assumption, not a result.
Not established for AHK-Cu. The Wnt and beta-catenin signalling pathway appears on several pages discussing this peptide. No primary AHK-Cu study in the evidence reviewed here tested it.
One correction belongs in this section. Several retail and reference pages list an increase in VEGF and a decrease in TGF-beta1 as AHK-Cu findings from the 2007 paper. Read the source carefully and those appear in its opening background, describing tripeptide-copper complex effects on dermal fibroblasts from earlier work. They are not reported as AHK-Cu measurements from that experiment. The distinction matters because those two claims anchor a great deal of downstream marketing.
The one study everything rests on
Here is the full citation, because a surprising number of pages get it wrong. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH and Kim KH published "The effect of tripeptide-copper complex on human hair growth in vitro" in *Archives of Pharmacal Research* in July 2007, volume 30, issue 7, pages 834 to 839. The PubMed identifier is 17703734 and the DOI is 10.1007/BF02978833. One of the highest-ranking AHK-Cu reference pages currently attributes this paper to *Annals of Dermatology*, which is a different journal entirely.
Two different models carried the work in that study. Researchers took human hair follicles and kept them alive in culture outside the body. That approach lets a follicle keep growing briefly under controlled conditions. They also grew human dermal papilla cells, the specialised cells at the base of a follicle that help regulate hair growth, in a dish.
Neither model predicts what happens on a person's scalp. An isolated follicle has no blood supply, no hormonal environment and no immune system around it. Cells in a dish are further removed still. Both are legitimate early research tools, and both sit near the bottom of any evidence hierarchy.
Concentrations ran from 10 to the minus 12 molar up to 10 to the minus 9 molar. Those are extraordinarily dilute solutions applied in controlled laboratory conditions. Nothing about that range translates into a quantity, a formulation or a use of any kind.
Now the finding that almost nobody reports. Flow cytometry showed that AHK-Cu at the highest tested concentration reduced the number of apoptotic dermal papilla cells. The paper states plainly that this decrease was not statistically significant. Apoptosis reduction is the mechanism most often cited as the reason this peptide supposedly protects follicles. The one measurement behind it did not reach significance.
Worth separating too is what the authors concluded from what the data showed. Their closing position is framed as a proposal, which is that AHK-Cu promotes hair follicle growth and that proliferation and reduced apoptosis may explain it. Proposing an explanation is normal scientific language for an untested interpretation. Later pages often repeat the proposal with the hedging removed.
The evidence at a glance
- Source: Pyo et al. 2007, *Archives of Pharmacal Research* — Model and study type: Human hair follicles ex vivo and cultured human dermal papilla cells, laboratory study — What it reports: Follicle elongation and cell proliferation at 10⁻¹² to 10⁻⁹ M, raised Bcl-2 to Bax ratio, lowered cleaved caspase-3 and PARP, apoptosis reduction not statistically significant — Limitations: Single unreplicated study, no human subjects, no reported control separating copper from peptide, conclusion framed by the authors as a proposal — Evidence strength: Low, and the only direct AHK-Cu evidence
- Source: GHK-Cu research literature — Model and study type: Varied laboratory, animal and human work on a different molecule — What it reports: Collagen, fibroblast, wound repair and angiogenesis findings attributed to GHK-Cu — Limitations: Studies a different peptide, so results cannot be assumed to apply here — Evidence strength: Not AHK-Cu evidence, analogy only
- Source: General copper biology — Model and study type: Broad biochemical and physiological literature — What it reports: Copper acts as a cofactor in enzyme systems including connective tissue formation — Limitations: Describes the element rather than this complex, with no AHK-Cu outcome measured — Evidence strength: Background context, not AHK-Cu evidence
What this evidence cannot tell you
Absences matter as much as findings here, and the list of absences is long. No human clinical trial of AHK-Cu has been published. No independent replication of the 2007 work appears in the evidence reviewed. Nothing compares it directly against another compound under controlled conditions. Long-term data does not exist, and neither does evidence tied to any specific formulation.
Single unreplicated results carry a particular kind of weakness. They can reflect something real, and they can also reflect the conditions, the cell line or ordinary variation. Replication is how the difference gets settled, which is why one study functions as a starting point rather than a conclusion.
Timelines deserve a direct answer because readers ask about them constantly. Week-by-week expectations circulate widely, usually as confident schedules running out to six or twelve months. No published AHK-Cu evidence supports any such timeline. Those schedules come from anecdote presented in the format of data.
Where the skin and collagen claims actually come from
Browse enough pages about this peptide and you will find collagen support, wound repair, firmer skin and improved blood vessel formation listed as benefits. Trace those claims and they nearly all lead back to GHK-Cu literature or to general copper biology. Those claims are analogies rather than findings.
Take collagen stimulation as a worked example. The research showing copper peptide effects on fibroblasts and collagen production was done on GHK-Cu. That molecule has a different sequence and a different history in the body. Transferring that result to AHK-Cu requires assuming the two behave alike, which no study has tested.
No direct AHK-Cu study of skin, collagen or wound healing appears in the evidence reviewed for this article. That is the honest position to take. Softening it into something like "may also support skin health" would quietly undo the distinction this section exists to draw.
AHK-Cu and GHK-Cu side by side
- Feature: Peptide sequence — AHK-Cu: Ala-His-Lys with Cu(II) — GHK-Cu: Gly-His-Lys with Cu(II)
- Feature: INCI name — AHK-Cu: Copper Tripeptide-3 — GHK-Cu: Copper Tripeptide-1
- Feature: Occurs naturally in humans — AHK-Cu: Not established — GHK-Cu: Yes, isolated from human plasma
- Feature: First described — AHK-Cu: 2007 study is the primary reference — GHK-Cu: Isolated in 1973
- Feature: Size of evidence base — AHK-Cu: One direct study — GHK-Cu: Hundreds of published papers
- Feature: Direct human evidence — AHK-Cu: None published — GHK-Cu: Human research exists, including cosmetic work
- Feature: Hair follicle research — AHK-Cu: One ex vivo and in vitro study — GHK-Cu: Multiple studies across models
- Feature: Skin and collagen claims — AHK-Cu: No direct study identified — GHK-Cu: Supported by its own literature
- Feature: Proposed mechanisms — AHK-Cu: Cell proliferation and reduced apoptosis, proposed by the authors — GHK-Cu: Multiple proposed mechanisms across tissue types
- Feature: Molecular identity clarity — AHK-Cu: Disputed CAS mapping and widely misquoted masses — GHK-Cu: Better documented and more consistently reported
- Feature: Principal uncertainty — AHK-Cu: Whether effects come from peptide, copper or complex — GHK-Cu: How laboratory findings translate to outcomes
- Feature: Evidence strength — AHK-Cu: Low, single unreplicated laboratory study — GHK-Cu: Stronger, though still mixed by claim and context
So which one is better. That question cannot be answered from the published record, and anyone answering it confidently is working from something other than evidence. What can be said is narrower and more useful. GHK-Cu has been studied far more, in more models, for longer. Greater study volume tells you where more is known, not which molecule performs better in any given situation.
A genuine comparison does not exist. No head-to-head trial of AHK-Cu against GHK-Cu appears in the evidence reviewed here. Running one properly would mean matching concentrations, using identical models, measuring the same endpoints, and including controls that separate copper effects from peptide effects. Until something like that is published, side-by-side rankings are opinion wearing a lab coat.
How AHK-Cu, GHK-Cu and minoxidil compare as evidence
These three get grouped in hair discussions constantly, which obscures how unlike their evidence bases are. Minoxidil has been tested in controlled human trials over decades, with regulatory review behind it. GHK-Cu has a substantial research literature spanning laboratory, animal and some human work. AHK-Cu has a single laboratory study behind it.
Their mechanisms differ just as sharply. Minoxidil's proposed action centres on blood flow and on the hair growth cycle, with a long history of investigation. What the 2007 study proposed for AHK-Cu concerns cell proliferation and cell survival in dermal papilla cells. Similar interest in hair outcomes does not mean similar biological action.
Nothing here constitutes a recommendation, and none of these evidence bases substitutes for another. A compound with controlled human trials and a compound with one in vitro study occupy different categories of knowledge entirely. Comparing them means comparing what is known, not ranking options.
Combination questions come up often, usually phrased as whether AHK-Cu can be used alongside minoxidil or GHK-Cu. No published study in the evidence reviewed examined any such combination. Absence of study is not evidence of compatibility or of conflict. It simply means the question has not been answered.
Three claims about AHK-Cu that do not hold up
It blocks DHT. No published AHK-Cu mechanism establishes any effect on the conversion of testosterone to dihydrotestosterone. Where this claim comes from is traceable. Some pages note a TGF-beta1 reduction, connect TGF-beta1 to androgen-related signalling in follicles, and compress that chain into a hormonal claim. Even setting aside that the TGF-beta1 material belongs to earlier tripeptide-copper work rather than the AHK-Cu measurements, a signalling association is not a blocking mechanism. Describing this peptide as a DHT blocker misstates what anyone has shown.
The effect definitely comes from the peptide. Testing a copper complex tells you about the complex. It cannot tell you whether the active contribution came from the peptide sequence, from the copper ion, or from the two together. That confound sits at the centre of the topic and almost nobody raises it. Settling it would require three arms tested in one experiment under identical endpoints. Those arms are the free AHK peptide without copper, a matched copper salt control, and the complex. No such comparison appears in the evidence reviewed here.
The specific numbers are real. Precise figures circulate widely, including fold increases in VEGF and FGF-7 and a percentage figure for follicle enlargement. Check them against the primary paper's own account of what it measured and they do not line up. FGF-7 does not appear among the reported measurements at all. Numbers carry authority precisely because they look checkable, which makes unsupported ones more damaging than vague claims.
What is known and unknown about safety
Start with what the record plainly shows. No human safety data for AHK-Cu appears in the evidence reviewed for this article. Cell cultures and isolated follicles cannot establish whether a substance is safe in people, because they contain none of the systems that determine safety. Metabolism, immune response, distribution and elimination are all absent from those models.
You will not find an adverse-effect list below, and the reason is deliberate. Publishing a list of side effects would imply that someone studied this peptide in people and recorded them. Nobody has published that kind of study. An invented list would read as more informative while being less true than an honest gap.
Copper itself carries general considerations worth noting as background. Copper allergy exists, and conditions affecting copper handling in the body, such as Wilson disease, are documented in the medical literature. Both describe copper rather than this complex, and neither derives from AHK-Cu research.
Purity figures deserve particular caution here. A high purity percentage on a document describes what an analytical method measured in a sample. It does not establish sterility, safety, biological activity or suitability for human use. Treating a purity number as a safety signal is one of the more common errors in this product category.
What research use only actually asserts
Research use only is a positioning statement about intended use, and it is widely misread as a quality claim. What the label asserts is quite narrow. The material is supplied for laboratory research purposes.
Here is what the label does not assert. It does not mean FDA approval, and it does not mean any regulatory body has reviewed the substance. It does not mean human safety has been demonstrated, because that requires human studies. Clinical efficacy is not implied, since efficacy requires trials that have not been run. Permission for human use is not granted, expressed or implied.
Product label statements and evidence claims are separate categories, and keeping them separate protects readers. A label describes what a seller states about a material. Evidence describes what researchers have measured and published. Neither one substitutes for the other, and this article makes no claim about any specific product's contents.
How to read an AHK-Cu label and what the paperwork proves
Analytical documentation answers three different questions, and conflating them causes most of the confusion. Identity asks whether the material is the molecule it claims to be. Purity asks what proportion of the sample the analytical method attributed to that molecule. Quantity or content asks how much material is actually present.
Each of those answers has real limits. Identity testing supports a molecular match under the method used and says nothing about sterility or activity. Purity reflects what one method detected, which means impurities that method cannot see stay invisible. Content figures depend on the assay and its assumptions. Our guide to reading a peptide certificate of analysis walks through how those documents are structured and where they stop.
Traceability is the question people skip. A document is only meaningful if it corresponds to the exact batch or lot in front of you. Generic documentation, or paperwork from a different lot, establishes nothing about the specific material. Evaluating that relationship is part of evaluating a supplier at all, which our guide to choosing a research peptide supplier covers in more depth.
Naming offers a quick practical check. A label reading Copper Tripeptide-1 is describing GHK-Cu, not AHK-Cu. One widely read cosmetic source has these names reversed. A reader trusting that source will confirm the wrong molecule while believing they verified it.
Formulation chemistry gets discussed often in cosmetic contexts, and several points recur. Copper peptide stability is described as pH sensitive. Chelating agents can compete for the copper ion. Vitamin C and some acids are commonly described as incompatible with copper peptides in formulation. Colour is sometimes offered as a freshness indicator, which is a weak check because colour can reflect several variables at once. These points describe formulation science as reported, and none of them is a preparation or application instruction.
What research would actually settle this
Replication comes first in that list. An independent group repeating the 2007 work, in comparable models with comparable endpoints, would tell the field whether the original observations hold.
Controlled human studies would answer the question readers actually care about, and nothing short of them can. Laboratory and ex vivo work generates hypotheses rather than outcomes.
A direct comparison against GHK-Cu, run under matched conditions, would replace the current guesswork about relative performance with something measurable.
Separating copper from peptide ranks as the most interesting unanswered question. An experiment testing the free peptide, a copper control and the complex side by side would finally show where any effect originates. None of this is predicted to happen, and the field may simply stay where it is.
The bottom line
AHK-Cu is a real molecule with a thin evidence base, and both halves of that sentence matter. One laboratory study, now almost twenty years old and apparently unreplicated, reported follicle elongation and cell proliferation. Its apoptosis finding fell short of statistical significance. Nothing from human research has been published. No study separates the peptide's contribution from the copper's.
Judged against GHK-Cu, the gap is not subtle. One molecule has decades of literature and a documented presence in human plasma, and the other has a single paper. Taking the evidence seriously here means describing it accurately, including how little of it there is.
